Global Information, Inc.
日商環球訊息有限公司
網站導覽
產業/市場分類
有興趣參與全球國際會議(展示會)嗎?
英文調查報告書

醫療資訊負責人:接觸關鍵意見領袖及建立關係

Medical Science Liaisons: Gaining Access and Forging Relationships with Key Opinion Leaders

出版商 Best Practices, LLC 聯絡我們
出版日期 2009/07 內容資訊 32 Pages
商品編碼 94430
價格 US $ 2,800 ~ Price List
US $ 2,800 PDF by E-mail (Single User License) & Hard Copy
US $ 8,400 PDF by E-mail (Site User License) + 1 Hard Copy
US $ 14,000 PDF by E-mail (Corporate User License) + 1 Hard Copy
本頁所標示之售價為不含購買者所在地消費稅之未稅價格,相關消費稅金將另行加至交易金額中
aaaaaaa
PDF by E-Mail
2個工作天後到貨
Hard Copy/CD-ROM
約5個工作天左右
TOC
此出版品為英文撰寫

Abstract

STUDY OVERVIEW

As companies compete for the attention of physicians, key opinion leaders (KOLs) and thought leaders, they increasingly use medical science liaisons (MSLs) to build and strengthen KOL relationships. As laws continue to restrict relationships between pharmaceutical companies and physicians, finding the right way to build and maintain relationships can have a dramatic impact on company success. This research uncovers the optimal size, mix and service frequencies of these elite medical specialist groups in an effort to build strong, productive relationships.

KEY TOPICS

  • Prelaunch Service Activities
  • PostLaunch Service Activities
  • Drivers of Group Size & Focus
  • Structuring & Aligning FieldBased Liaisons with Sales Organizations
  • Optimal Call Frequencies and Service Levels with Thought Leaders

KEY METRICS

  • Market Monitoring Systems
  • Competition Monitoring
  • Liaison Value Tracking
  • Liaison Sales Force Size Determinants
  • Product Lifecycle
  • Thought Leader Coverage
  • Franchise Objectives
  • Revenue Levels
  • Call Frequency
  • Sales Force Productivity
  • Liaison Productivity

METHODOLOGY

This research was based on benchmark survey data and executive interviews of more than 25 participants from pharmaceutical, biotechnology, medical devices and other industries requiring highperforming sales personnel.

INDUSTRIES PROFILED

Pharmaceutical, Biotechnology, Medical Devices

COMPANIES PROFILED

AstraZeneca; Axcan Pharma Inc.; Boehringer Ingelheim; BristolMyers Squibb; Cardiac Science Corp.; CSL Behring; Eli Lilly and Company; Focus Technologies; Genentech; Innovex; Janssen; Medtronic; Bertek; Novartis; Novo Nordisk; Organon; Schering Plough; Shire; TTY Biopharm; UCB; Vertex

Table of Contents

  • STUDY OVERVIEW
  • THE BENCHMARK CLASS
  • KEY FINDINGS AND INSIGHTS
  • SPECIALIST ROLES AND SERVICE SCOPE
    • PreLaunch MSL Roles
    • PostLaunch MSL Roles
    • Manage Thought Leaders to Optimize Product Impact
    • Preand PostLaunch Activities
    • Drivers for FieldForce Size
    • Deploying Liaisons Into Field
    • Stakeholder Needs Analysis
  • RELATIONSHIP MANAGEMENT STANDARDS OF EXCELLENCE
    • Thought Leader Segment Definitions
    • Developing Relationships Through Liaisons
    • Growing New KOLs through Reps & Liaisons
    • Maintaining KOLs through Reps & Liaisons
  • MANAGING, SHIFTING & FORECASTING RESOURCES
    • Span of Control: Managers to Specialists
    • Drivers for Increasing Number of FieldBased Medical Specialists
    • Drivers for Decreasing Number of FieldBased Medical Specialists
    • Resource Shifting and Forecasting
    • Automatic Resource Decrease
    • Triggers for Shifting Liaisons
    • Path Forward
    • Areas for Further Research
  • ABOUT BEST PRACTICES, LLC
有關報告
Top